Beyond oncology, this high-throughput approach also holds promise in neurodegenerative diseases, where protein aggregates like tau in Alzheimer’s [72] or α-synuclein in Parkinson’s disease [73,74] have been shown to play central roles in disease initiation and progression, with ongoing research investigating their potential as biomarkers for early diagnosis and disease monitoring [75,76,77,78]. The gene discussed is MAPT; the disease is Parkinson disease.